PIK3CA and neoplasm: Furthermore, it is reported that the overall clinical response rate of gastric cancer patients to PD-1 inhibition was significantly higher in patients with PD-L1+ tumor cells, PIK3CA mutation, MMR deficiency, and EBV+ tumors [53,74], suggesting these subsets could be candidates for immunotherapy.